NAFLD

Amino acid-based therapy for Non-alcoholic fatty liver disease (NAFLD): D-Serine promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD) via down regulation of its target gene, 10/December/2017, 6.07 am
Amino acid-based therapy for Non-alcoholic fatty liver disease (NAFLD): D-Serine promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD) via down regulation of its target gene, 10/December/2017, 6.07 am 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while only 6-25% of Asian populations suffer from it; (2) 75 to 100 million…

read more

Vitamin-based therapy for Non-alcoholic fatty liver disease (NAFLD): Calcitriol, a form of Vitamin-D, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 27/September/2017, 6.31 am
Vitamin-based therapy for Non-alcoholic fatty liver disease (NAFLD): Calcitriol, a form of Vitamin-D, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 27/September/2017, 6.31 am 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while only 6-25% of Asian populations suffer from it; (2) 75 to 100 million…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Lysophosphatidic acid (LPA) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 25/November/2017, 3.45 pm
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Lysophosphatidic acid (LPA) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 25/November/2017, 3.45 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetic Neuropathy, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 16/November/2017, 5.43 am
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetic Neuropathy, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 16/November/2017, 5.43 am 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Victoza/Saxenda, an anti-hyperglycemic drug, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 12/November/2017, 11.15 pm
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Victoza/Saxenda, an anti-hyperglycemic drug, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 12/November/2017, 11.15 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Mangiferin, isolated from Mangifera Indica, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 11/November/2017, 11.40 pm
Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Mangiferin, isolated from Mangifera Indica, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 11/November/2017, 11.40 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more
Start Typing